Fax: (847) 570-8033
Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy
Version of Record online: 4 JUN 2003
Copyright © 2003 American Cancer Society
Volume 98, Issue 2, pages 406–412, 15 July 2003
How to Cite
Cella, D., Pulliam, J., Fuchs, H., Miller, C., Hurd, D., Wingard, J. R., Sonis, S. T., Martin, P. J. and Giles, F. (2003), Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer, 98: 406–412. doi: 10.1002/cncr.11505
- Issue online: 2 JUL 2003
- Version of Record online: 4 JUN 2003
- IntraBiotics Pharmaceuticals, Inc. (Mountain View, CA)
- oral mucositis;
- oral pain;
- iseganan HCl
No single oral mucositis (OM) assessment scale is universally accepted; the most commonly used scales are deficient because they combine subjective and objective measures and do not capture the patient's perspective. Because pain is the hallmark symptom of OM, the authors sought to determine whether a simple measure of patient-reported pain was correlated with objective, physician-assessed measures of OM. The findings of the current study may provide a clinical context for understanding the relation between objective indicators and patients' perceptions of OM.
Three hundred twenty-three patients receiving stomatotoxic chemotherapy and randomized to receive either iseganan or placebo for treatment of OM underwent periodic objective and subjective evaluations of OM. Objective measures included clinician scoring of stomatitis and dysphagia using the National Cancer Institute Common Toxicity Criteria scales. A subjective measure was obtained by having patients complete a questionnaire (with questions based on an 11-point numeric scale) regarding oral pain.
More than 90% of scheduled oral assessments were obtained. Mouth pain scores were closely related to stomatitis and dysphagia; peak mouth pain coincided with peak stomatitis and dysphagia. Analgesic use increased by 0.7 days for each unit rise on the pain scale. Patients receiving iseganan had a significantly lower level of peak mouth pain than did patients receiving placebo (P = 0.041).
A separate measurement of patient-reported pain was useful for capturing the patient's perspective on OM and was correlated with the physician's objective assessment. These findings support the use of a simple, patient-reported rating of mouth pain as a clinically relevant and responsive endpoint in clinical trials. This rating system also may provide a straightforward method of following OM in clinical practice. Cancer 2003;98:406–12. © 2003 American Cancer Society.